Apogee Therapeutics
Subsidiary of AbbVie (ABBV)
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | IL-13Monoclonal antibody | Atopic DermatitisAsthma | |
| Phase 1 | IL-4R-alphaMonoclonal antibody | Chronic Obstructive Pulmonary Disease | |
| Phase 1 | OX40LMonoclonal antibody | Atopic Dermatitis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (13)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $67M | $106M+ $866M short-term inv. | $86M-$71M operating cash flow | report ↗ |
View 12 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0 | — | $1.3B | — | report ↗ |
| 2025-Q3 | — | $54M | $108M+ $419M short-term inv. | $65M-$54M operating cash flow | report ↗ |
| 2025-Q2 | — | $56M | $124M+ $381M short-term inv. | $66M-$62M operating cash flow | report ↗ |
| 2025-Q1 | — | $46M | $107M+ $406M short-term inv. | $55M-$48M operating cash flow | report ↗ |
| 2024-Q3 | — | $46M | $119M+ $407M short-term inv. | $49M-$43M operating cash flow | report ↗ |
| 2024-Q2 | — | $33M | $308M+ $369M short-term inv. | $34M-$29M operating cash flow | report ↗ |
| 2024-Q1 | — | $29M | $486M+ $331M short-term inv. | $32M-$32M operating cash flow | report ↗ |
| 2023-Q3 | — | $17M | $188M+ $235M short-term inv. | $21M-$20M operating cash flow | report ↗ |
| 2023-Q2 | — | $14M | $125M | $19M-$15M operating cash flow | report ↗ |
| 2023-Q1 | — | $8.5M | $141M | $13M-$11M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.9M | $2.6M | $20M | report ↗ |
| 2022-Q2 | — | $1.4M | $5.0M | $1.8M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $215M | $132M+ $599M short-term inv. | $64M-$227M operating cash flow | report ↗ |
Apogee Therapeutics reported no revenue for fiscal year 2025, with R&D spend of $214.71M, up 27.9% YoY. Cash and equivalents were $131.55M, and the company reported a net loss of $255.84M.
The 10-K details clinical progress across its pipeline, including positive 16-week APEX Part A data for zumilokibart in atopic dermatitis, ahead-of-schedule completion of Part B enrollment with 347 patients, and expected 16-week Part B topline data in Q2 2026 with a potential Phase 3 initiation in the second half of 2026. Positive interim results were also reported for the APG808 Phase 1b asthma trial, the APG333 Phase 1 trial, and the zumilokibart Phase 1b asthma trial. The APG279 Phase 1b trial against DUPIXENT is ongoing with a readout expected in the second half of 2026.